Combined therapy of CAR-IL-15/IL-15Rα-T cells and GLIPR1 knockdown in cancer cells enhanced anti-tumor effect against gastric cancer

• Published in: Journal of translational medicine 2024-02, Vol.22 (1), p.171-13, Article 171
• Main Authors: Ye, Jianbin, Liu, Qiaoyuan, He, Yunxuan, Song, Zhenkun, Lin, Bao, Hu, Zhiwei, Hu, Juanyuan, Ning, Yunshan, Cai, Cheguo, Li, Yan
• Format: Article
• Language: English
• Subjects: Antigens; Bioluminescence; Cancer therapies; CAR-T; Cell growth; Cell migration; Cell proliferation; Cell therapy; Chimeric antigen receptors; Cholecystokinin; Cloning; Combined therapy; Cytokines; Cytotoxicity; Enzyme-linked immunosorbent assay; Flow cytometry; Gastric cancer; GLIPR1; IL-15/IL-15Rα; Interleukin 15; Lymphocytes; Lymphocytes T; Malignancy; Patients; Software; Solid tumor; Solid tumors; Tumor microenvironment
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-024-04982-6

Chimeric antigen receptor (CAR) T cell therapy has shown remarkable responses in hematological malignancies with several approved products, but not in solid tumors. Patients suffer from limited response and tumor relapse due to low efficacy of CAR-T cells in the complicated and immunosuppressive tumor microenvironment. This clinical challenge has called for better CAR designs and combined strategies to improve CAR-T cell therapy against tumor changes. In this study, IL-15/IL-15Rα was inserted into the extracellular region of CAR targeting mesothelin. In-vitro cytotoxicity and cytokine production were detected by bioluminescence-based killing and ELISA respectively. In-vivo xenograft mice model was used to evaluate the anti-tumor effect of CAR-T cells. RNA-sequencing and online database analysis were used to identify new targets in residual gastric cancer cells after cytotoxicity assay. CAR-T cell functions were detected in vitro and in vivo after GLI Pathogenesis Related 1 (GLIPR1) knockdown in gastric cancer cells. Cell proliferation and migration of gastric cancer cells were detected by CCK-8 and scratch assay respectively after GLIPR1 were overexpressed or down-regulated. CAR-T cells constructed with IL-15/IL-15Rα (CAR-ss-T) showed significantly improved CAR-T cell expansion, cytokine production and cytotoxicity, and resulted in superior tumor control compared to conventional CAR-T cells in gastric cancer. GLIPR1 was up-regulated after CAR-T treatment and survival was decreased in gastric cancer patients with high GLIPR1 expression. Overexpression of GLIPR1 inhibited cytotoxicity of conventional CAR-T but not CAR-ss-T cells. CAR-T treatment combined with GLIPR1 knockdown increased anti-tumor efficacy in vitro and in vivo. Our data demonstrated for the first time that this CAR structure design combined with GLIPR1 knockdown in gastric cancer improved CAR-T cell-mediated anti-tumor response.